Dados B3 › BLAU3
BLAU3 (Blau Farmacêutica): has profit grown?
BLAU3 (Blau Farmacêutica): in 2025, net income attributable to controlling shareholders was R$ 295.0 million, up 36% versus 2024 (a profit of R$ 217.2 million); five years earlier (2020), a profit of R$ 254.3 million.
| Year | Profit (loss) | Change |
|---|---|---|
| 2025 | R$ 295.0 million | up 36% |
| 2024 | R$ 217.2 million | down 13% |
| 2023 | R$ 249.8 million | down 31% |
| 2022 | R$ 362.8 million | up 12% |
| 2021 | R$ 325.2 million | up 28% |
| 2020 | R$ 254.3 million | up 27% |
| 2019 | R$ 200.2 million | up 62% |
| 2018 | R$ 123.3 million | up 20% |
| 2017 | R$ 103.1 million | — |
Annual statements (DFP). Profit attributable to controlling shareholders when the company reports it; otherwise total net income. Fact with its source; not investment advice.
Check it yourself
- Open data, no key needed for WEGE3 and with a free key for any company:
https://dadosb3.com/empresas/BLAU3/fatos - Every annual figure comes from the DFP filed with the CVM (dados.cvm.gov.br); dividends come from B3.
- The company page shows the account each number came from: BLAU3.
Dividends · Debt · Full page · How much it returned · plain text for AI
Numbers on this page are live. Data version 2026-10-01-cfo-metodo-direto · page generated 2026-10-17 16:14 UTC. If this does not match /saude, you are reading a cached copy.
Sources: CVM (open data, ODbL) and B3 (COTAHIST). Not affiliated with B3 or the CVM. Not investment advice.
Numbers on this page are live. Data version 2026-10-01-cfo-metodo-direto · page generated 2026-10-17 16:14 UTC. If this does not match /saude, you are reading a cached copy.